Rocket Pharmaceuticals, Inc. (RCKT)
$
2.62
+0.14 (5.34%)
Key metrics
Financial statements
Free cash flow per share
-1.9336
Market cap
694.9 Million
Price to sales ratio
0
Debt to equity
0.0615
Current ratio
9.1896
Income quality
0.8088
Average inventory
0
ROE
-0.6492
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Rocket Pharmaceuticals, Inc., along with its subsidiaries, functions as a multi-platform biotechnology entity with a primary focus on innovating gene therapies for rare and severe diseases. The gross profit stands at $0.00 highlighting the company's profitability from core operations. Currently, Rocket Pharmaceuticals is advancing three clinical-stage ex vivo lentiviral vector programs targeting Fanconi anemia, which involves a genetic defect that impairs the bone marrow’s ability to generate healthy blood cells, leukocyte adhesion deficiency-I, a disorder that disrupts immune system functionality, and pyruvate kinase deficiency, a rare genetic disorder characterized by chronic non-spherocytic hemolytic anemia due to red blood cell issues. Additionally, the company's commitment to research is reflected in its clinical-stage in vivo adeno-associated virus program focused on Danon disease, a lysosomal-associated disorder that can result in premature death from heart failure. The total costs and expenses for the company are $0.00 reflecting its overall spending, while the company reported depreciation and amortization expenses of $0.00 which indicate the wear and tear of its assets. Furthermore, the net income ratio is 0.00 revealing the company's profitability margin, and the reported selling, general, and administrative expenses of $101,961,000.00 illustrate its operational overhead costs. Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, and has secured various license agreements with prestigious institutions, enhancing its research capabilities and collaborative efforts. In terms of its stock performance, the stock is affordable at $2.62 making it an appealing option for budget-conscious investors. With a high average trading volume of 4,186,459.00 the stock indicates strong liquidity, which is beneficial for traders and investors alike. Currently, with a market capitalization of $282,273,560.00 the company is classified as a small-cap player within the biotechnology sector. It plays a significant role in the Biotechnology industry, contributing to the evolving landscape of biopharmaceutical innovation. Moreover, it belongs to the Healthcare sector, which is pivotal in driving innovation and sustainable growth in the market. This combination of factors underscores Rocket Pharmaceuticals’ strategic position, emphasizing its commitment to addressing critical healthcare needs through its advanced therapeutic programs.
Is Rocket Pharmaceuticals, Inc. (RCKT) a good investment?
Investing in Rocket Pharmaceuticals, Inc. (RCKT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Rocket Pharmaceuticals, Inc. (RCKT)'s stock forecast?
Analysts predict Rocket Pharmaceuticals, Inc. stock to fluctuate between $2.19 (low) and $26.98 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Rocket Pharmaceuticals, Inc.'s market capitalization?
As of 2025-05-29, Rocket Pharmaceuticals, Inc.'s market cap is $282,273,560, based on 107,738,000 outstanding shares.
How does Rocket Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Rocket Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Rocket Pharmaceuticals, Inc. (RCKT) stock?
To buy Rocket Pharmaceuticals, Inc. (RCKT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for RCKT. Place an order (Market, Limit, etc.).
What is the best time to invest in Rocket Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Rocket Pharmaceuticals, Inc. stock ever split?
Rocket Pharmaceuticals, Inc.'s last stock split was 1:4 on 2018-01-05.
How did Rocket Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.73 | Growth: -6.51%.
Where can I find Rocket Pharmaceuticals, Inc.'s investor relations reports?
Visit https://rocketpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Rocket Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Rocket Pharmaceuticals, Inc. stock?
All-time high: $67.48 (2021-02-08) | All-time low: $2.19 (2025-05-27).
What are the key trends affecting Rocket Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
globenewswire.com
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
globenewswire.com
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT.
benzinga.com
Rocket Pharmaceuticals Inc RCKT announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) and intellectual disability.
benzinga.com
Rocket Pharmaceuticals Inc RCKT announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) and intellectual disability.
proactiveinvestors.com
Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) sank nearly 60% on Tuesday morning after the company disclosed that the US Food and Drug Administration had placed a clinical hold on its pivotal Phase II trial for Danon disease, a rare genetic heart disorder, following the death of a patient in the study. The patient experienced a serious adverse event (SAE) of capillary leak syndrome and subsequently died due to an acute systemic infection, according to reports.
businesswire.com
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced preliminary data from the Phase 1 clinical trial of RP-A601 for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). RP-A601 showed a well-tolerated safety profile with no dose-limiting toxicities, increased PKP2 protein expressi.
businesswire.com
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Thera.
See all news
